We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK Watchdog Says Dendreon’s Prostate Cancer Drug Is Too Pricy
UK Watchdog Says Dendreon’s Prostate Cancer Drug Is Too Pricy
A UK healthcare cost watchdog has recommended against national coverage of Dendreon’s novel prostate cancer treatment Provenge, deeming it too expensive.